Last reviewed · How we verify
B arm (FLAG-IDA)
FLAG-IDA is a chemotherapy combination regimen that uses fludarabine, cytarabine, and idarubicin to induce apoptosis in leukemic cells through DNA damage and inhibition of DNA synthesis.
FLAG-IDA is a chemotherapy combination regimen that uses fludarabine, cytarabine, and idarubicin to induce apoptosis in leukemic cells through DNA damage and inhibition of DNA synthesis. Used for Acute myeloid leukemia (AML), relapsed or refractory, Acute lymphoblastic leukemia (ALL), relapsed or refractory.
At a glance
| Generic name | B arm (FLAG-IDA) |
|---|---|
| Also known as | Fludarabine, Cytarabine, Idarubicin, G-CSF |
| Sponsor | Polish Adult Leukemia Group |
| Drug class | Chemotherapy combination regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
FLAG-IDA combines three cytotoxic agents: fludarabine (a purine analog that inhibits DNA synthesis), cytarabine (a pyrimidine analog that incorporates into DNA), and idarubicin (a topoisomerase II inhibitor that causes DNA strand breaks). Together, these agents work synergistically to kill rapidly dividing leukemic cells by overwhelming their DNA repair mechanisms and triggering programmed cell death.
Approved indications
- Acute myeloid leukemia (AML), relapsed or refractory
- Acute lymphoblastic leukemia (ALL), relapsed or refractory
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia, anemia)
- Infection
- Mucositis
- Nausea and vomiting
- Hepatotoxicity
- Neurotoxicity
Key clinical trials
- A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years Old (PHASE3)
- Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- B arm (FLAG-IDA) CI brief — competitive landscape report
- B arm (FLAG-IDA) updates RSS · CI watch RSS
- Polish Adult Leukemia Group portfolio CI